Holen Sie sich die Stockscreener-App
41.35
3.43%
1.37
Handel nachbörslich:
41.35
Schlusskurs vom Vortag:
$39.98
Offen:
$37.4
24-Stunden-Volumen:
746.92K
Relative Volume:
1.07
Marktkapitalisierung:
$2.59B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-230.66M
KGV:
-9.9061
EPS:
-4.1742
Netto-Cashflow:
$-148.12M
1W Leistung:
-8.86%
1M Leistung:
-4.42%
6M Leistung:
+87.36%
1J Leistung:
+311.85%
1-Tages-Spanne:
$36.35
$42.00
1-Wochen-Bereich:
$36.35
$46.09
52-Wochen-Spanne:
$8.29
$47.84
Kodiak Sciences Inc Stock (KOD) Company Profile
Firmenname
Kodiak Sciences Inc
Sektor
Branche
Telefon
650-281-0850
Adresse
1250 PAGE MILL RD, PALO ALTO, CA
Compare KOD vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KOD
Kodiak Sciences Inc
|
41.35 | 2.72B | 0 | -230.66M | -148.12M | -4.1742 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Kodiak Sciences Inc Stock (KOD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-11 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-10-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-09-25 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2025-09-22 | Eingeleitet | Jefferies | Buy |
| 2025-08-14 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2024-12-09 | Hochstufung | Jefferies | Hold → Buy |
| 2024-09-05 | Eingeleitet | H.C. Wainwright | Neutral |
| 2023-12-11 | Fortgesetzt | Goldman | Sell |
| 2023-11-17 | Hochstufung | CapitalOne | Equal Weight → Overweight |
| 2023-07-27 | Herabstufung | UBS | Buy → Neutral |
| 2023-07-25 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2023-07-25 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-07-24 | Herabstufung | CapitalOne | Overweight → Equal Weight |
| 2023-07-24 | Herabstufung | Jefferies | Buy → Hold |
| 2022-11-15 | Eingeleitet | CapitalOne | Overweight |
| 2022-08-02 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-02-24 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-02-11 | Eingeleitet | Goldman | Buy |
| 2022-02-02 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-05-11 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2021-03-12 | Eingeleitet | Evercore ISI | Outperform |
| 2021-03-01 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2021-02-17 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2021-01-25 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-12-16 | Eingeleitet | UBS | Buy |
| 2020-12-11 | Eingeleitet | Citigroup | Neutral |
| 2020-11-30 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-11-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-13 | Herabstufung | Goldman | Buy → Neutral |
| 2020-03-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-03-03 | Eingeleitet | Goldman | Buy |
| 2020-02-18 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-02-06 | Eingeleitet | SunTrust | Buy |
| 2020-01-08 | Eingeleitet | ROTH Capital | Buy |
| 2020-01-03 | Eingeleitet | Jefferies | Buy |
| 2019-12-24 | Eingeleitet | JP Morgan | Overweight |
| 2019-10-15 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-02-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2018-10-29 | Eingeleitet | Barclays | Overweight |
| 2018-10-29 | Eingeleitet | BofA/Merrill | Buy |
| 2018-10-29 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Kodiak Sciences Inc Aktie (KOD) Neueste Nachrichten
Kodiak Sciences (KOD) Advances Late-Stage Trials Amid High Valua - GuruFocus
California State Teachers Retirement System Has $1.12 Million Stock Holdings in Kodiak Sciences Inc. $KOD - marketbeat.com
Wall Street Zen Downgrades Kodiak Sciences (NASDAQ:KOD) to Sell - marketbeat.com
UBS Maintains Kodiak Sciences(KOD.US) With Buy Rating, Maintains Target Price $80 - Moomoo
Kodiak Sciences (NASDAQ:KOD) Shares Gap DownTime to Sell? - marketbeat.com
Kodiak's Q2 Loss Wider Than Expected, Pipeline Development in Focus - theglobeandmail.com
Kodiak Sciences misses Q2 estimates, shares fall 5% By Investing.com - Investing.com Nigeria
Kodiak Sciences (NASDAQ:KOD) Releases Earnings Results, Misses Estimates By $0.09 EPS - marketbeat.com
Kodiak Sciences misses Q2 estimates, shares fall 5% - Investing.com
Kodiak Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Kodiak Sciences posts Q2 2026 net loss of $65.6M, cash $125.9M; DAYBREAK, PEAK readouts due Sept–Dec 2026 - TradingView
BRIEF-Kodiak Sciences Q2 Net Income USD -65.643 Million - TradingView
Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results - Yahoo Finance
Kodiak Sciences Inc. (KOD) stock price, news, quote and history - Yahoo Finance UK
Kodiak Sciences Enrols First Patients in Phase III ALTO Trial of KSI-501 for Diabetic Macular Edema - BioPharma APAC
KOD Begins Late-Stage Study of KSI-501 in Diabetic Macular Edema - TradingView
Kodiak Sciences Inc (KOD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Kodiak Sciences Announces First Patients Enrolled In Global Phase 3 Alto Trial Of Ksi-501 In Patients With Diabetic Macular Edema - TradingView
Kodiak Sciences (KOD) Begins Enrollment for Phase 3 ALTO Trial T - GuruFocus
Kodiak Sciences enrolls first patients in phase 3 DME trial - Investing.com
Kodiak Sciences starts Phase 3 trial for KSI-50... - Pluang
Kodiak Sciences enrolls first patients in phase 3 DME trial By Investing.com - Investing.com UK
Kodiak’s Eye Trial Tests Dosing Up to Six Months Apart - Stock Titan
Net margin % of Kodiak Sciences, Inc. – HAM:K27 - TradingView
Return on assets % of Kodiak Sciences, Inc. – HAM:K27 - TradingView
Kodiak Sciences, Inc. Statistics – HAM:K27 - TradingView
Kodiak Sciences (KOD) Is Up 9.1% After Advancing KSI-101 Phase 3 PEAK Trial Enrollment – Has The Bull Case Changed? - Sahm
The Manufacturers Life Insurance Company Acquires 29,121 Shares of Kodiak Sciences Inc. $KOD - marketbeat.com
Kodiak completes enrollment in first KSI-101 trial cohort By Investing.com - Investing.com India
LifeSci Capital Maintains Kodiak Sciences(KOD.US) With Buy Rating, Maintains Target Price $65 - Moomoo
Kodiak completes enrollment in first KSI-101 trial cohort - Investing.com
Kodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical Data Release Remains on Track for December 2026 - Yahoo Finance
Kodiak Sciences (KOD) Expected to Post Earnings on Wednesday - marketbeat.com
KOD Maintained by JP Morgan -- Price Target Raised to $66.00 - GuruFocus
J.P. Morgan Maintains Kodiak Sciences(KOD.US) With Buy Rating, Raises Target Price to $66 - Moomoo
Janus Henderson Group PLC Raises Stake in Kodiak Sciences Inc. $KOD - marketbeat.com
57,400 Shares in Kodiak Sciences Inc. $KOD Acquired by Swiss National Bank - MarketBeat
KOD News | KODIAK SCIENCES INC (NASDAQ:KOD) - ChartMill
Kodiak Sciences Inc. (NASDAQ:KOD) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Kodiak Sciences, Inc. Revenue Breakdown – BMV:KOD - TradingView
Kodiak Sciences Inc (KOD) Institutional Confidence - TradingKey
Kodiak Sciences Inc (KOD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Kodiak Sciences Inc Revenue Breakdown – BOATS:KOD - TradingView
Kodiak Sciences Inc (KOD) Cash Flow - TradingKey
Kodiak Sciences Inc (KOD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
KOD|Kodiak Sciences Inc|Price:42.020|Chg%:+0.610 - TradingKey
Kodiak Sciences Inc (KOD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Kodiak Sciences Inc (KOD) Valuation: PE, PB & Fair Value Analysis - TradingKey
Kodiak Sciences Inc (KOD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Kodiak Sciences Inc (KOD) Income Statement - tradingkey.com
Kodiak Sciences, Inc. Revenue Breakdown – LS:A2N6P0 - TradingView
Finanzdaten der Kodiak Sciences Inc-Aktie (KOD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):